Mumbai, April 20, 2018: Cadila Healthcare said that company has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a wholly owned subsidiary of the company and consequently, Bremer ceased to be a subsidiary of the company.
The company received consideration at enterprise value of Euro 22,63,431 of which share sale value is Euro 8,27,344 and loan value (extended by Zydus International – a wholly owned subsidiary of the company) is Euro 14,36,087.
United News of India
